/MAAT.PA
MAAT.PA Stock - MaaT Pharma S.A.
Healthcare|BiotechnologyPAR
$4.15+2.22%
+$0.09 (+2.22%) • Dec 23
62
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.28
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $4.57
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MAAT.PA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.11 – $4.19
TARGET (TP)$4.77
STOP LOSS$3.82
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.07
52W High$9.96
52W Low$3.55
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.22M | $2.23M | $1.43M | $972,000 | N/A |
| Gross Profit | $1.97M | $784,000 | $1.09M | $806,000 | $-164,000 |
| Gross Margin | 61.1% | 35.2% | 76.3% | 82.9% | N/A |
| Operating Income | $-28,428,000 | $-19,943,000 | $-13,556,000 | $-8,893,000 | $-7,388,000 |
| Net Income | $-28,904,000 | $-19,717,000 | $-13,713,000 | $-9,019,000 | $-5,350,000 |
| Net Margin | -898.8% | -885.0% | -959.0% | -927.9% | N/A |
| EPS | $-2.20 | $-1.73 | $-1.39 | $-3.72 | $-25.68 |
Company Overview
MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
MAAT.PABeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-1.15
Q2 2025
EPS Surprise History
Q4 21
No data
Q2 22
No data
Q4 22
No data
Q2 23
No data
Q4 23
No data
Q2 24
No data
Q3 24
No data
Q2 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Sep 17, 2025 | $-1.06 | — | — | — |
Q2 2025 | May 13, 2025 | — | $-1.15 | — | — |
Q3 2024 | Sep 19, 2024 | — | $-1.05 | — | — |
Q2 2024 | Apr 3, 2024 | — | $-0.97 | — | — |
Q4 2023 | Nov 9, 2023 | — | $-0.76 | — | — |
Q2 2023 | May 9, 2023 | — | $-0.64 | — | — |
Q4 2022 | Nov 8, 2022 | — | $-0.75 | — | — |
Q2 2022 | Jun 2, 2022 | — | $-0.65 | — | — |
Q4 2021 | Oct 20, 2021 | — | $-1.96 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-15.18 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-10.50 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-16.10 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-16.10 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-2.20 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-2.20 | — | — |
Latest News
Loading news...
Frequently Asked Questions about MAAT.PA
What is MAAT.PA's current stock price?
MaaT Pharma S.A. (MAAT.PA) is currently trading at $4.15 per share. The stock has moved +2.22% today.
What is the analyst price target for MAAT.PA?
No analyst price targets are currently available for this stock.
What sector is MaaT Pharma S.A. in?
MaaT Pharma S.A. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the PAR exchange.
What is MAAT.PA's market cap?
MaaT Pharma S.A. has a market capitalization of $0.06 billion, making it a small-cap company.
Does MAAT.PA pay dividends?
No, MaaT Pharma S.A. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAB.PA
AB Science S.A.
$1.35
Mkt Cap: $0.1B
AELIS.PA
Aelis Farma S.A.
$1.07
Mkt Cap: $0.0B
AFME.PA
Affluent Medical S.A.
$2.01
Mkt Cap: $0.1B
ALCOX.PA
Nicox S.A.
$0.29
Mkt Cap: $0.0B
ALDVI.PA
Advicenne S.A.
$1.75
Mkt Cap: $0.0B
ALGAE.PA
Fermentalg
$0.44
Mkt Cap: $0.0B
ALKLH.PA
Klea Holding
$0.23
Mkt Cap: $0.1B
ALSEN.PA
Sensorion S.A.
$0.32
Mkt Cap: $0.1B
ALVIO.PA
Valerio Therapeutics S.A.
$0.11
Mkt Cap: $0.0B
SIGHT.PA
GenSight Biologics S.A.
$0.11
Mkt Cap: $0.0B
Explore stocks similar to MAAT.PA for comparison